Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX

Publisher： Karger

E-ISSN： 1423-0232|79|1-2|136-143

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.1-2, 2010-12, pp. : 136-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Outcomes of Reintroducing Oxaliplatin to Patients with Colorectal Cancer after Mild Hypersensitivity Reactions

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 323-327

Karger

Access to resources Recommend Favorite

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 10, 2015-11 ,pp. : 2470-2477

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk

By  

Oncology, Vol. 75, Iss. 3-4, 2008-10 ,pp. : 215-223

Karger

Access to resources Recommend Favorite

Adjuvant FOLFOX Chemotherapy and Splenomegaly in Patients with Stages II–III Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 363-368

Karger

Access to resources Recommend Favorite

Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 254-265

Karger

Access to resources Recommend Favorite